Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 3.95 USD -2.71%
Market Cap: 1.2B USD

Wall Street
Price Targets

ABCL Price Targets Summary
Abcellera Biologics Inc

Wall Street analysts forecast ABCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABCL is 9.33 USD with a low forecast of 5.05 USD and a high forecast of 17.85 USD.

Lowest
Price Target
5.05 USD
28% Upside
Average
Price Target
9.33 USD
136% Upside
Highest
Price Target
17.85 USD
352% Upside
Abcellera Biologics Inc Competitors:
Price Targets
SFZN
Siegfried Holding AG
31% Upside
CRL
Charles River Laboratories International Inc
3% Upside
CDXS
Codexis Inc
153% Upside
BICO
BICO Group AB
76% Upside
LONN
Lonza Group AG
17% Upside
BIOT
Biotage AB
3% Upside
BANB
Bachem Holding AG
24% Upside
ADPT
Adaptive Biotechnologies Corp
17% Upside

Revenue
Forecast

Revenue Estimate
Abcellera Biologics Inc

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 3 years is 18%.

20%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Abcellera Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Abcellera Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABCL's stock price target?
Price Target
9.33 USD

According to Wall Street analysts, the average 1-year price target for ABCL is 9.33 USD with a low forecast of 5.05 USD and a high forecast of 17.85 USD.

What is Abcellera Biologics Inc's Revenue forecast?
Projected CAGR
18%

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 3 years is 18%.

Back to Top